ArticleFrontiers in pharmacology2026
HLA allele profiling and association in Thai patients with confirmed beta-lactam hypersensitivity: an NGS-based analysis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Beta-lactams (BLs) are the most common reported antibiotics associated with hypersensitivity reactions (HSRs). However, evidence for human leukocyte antigen (HLA) associations with beta-lactam hypersensitivity reaction (BL-HSR) remains limited and population-specific, particularly in the Thai population. Objectives: This study aims to explore HLA profiles and investigate associations between HLA class I and II alleles and confirmed BL-HSR in Thai adults, across immediate reactions (IR), non-immediate reactions with mild skin eruption (NIR-mild), and severe cutaneous adverse reactions (SCARs), and to contextualize these findings with regional data. Methods: This study was based on a case-conrtol design with exploratory analysis approach. For cases, we enrolled adult patients with confirmed BL-HSR from three Thai tertiary hospitals. IR and NIR-mild cases were confirmed by positive skin testing and/or drug provocation testing, while SCAR cases were clinically confirmed. Their blood samples underwent whole exome sequencing, and HLA typing was performed. For control group, we derived allele frequency data of HLA genes in Thai populations from previous nationwide studies previous nationwide studies and databases. HLA allele associations were assessed by Fisher's exact test with Bonferroni correction. Subgroup analyses were conducted based on reaction types and culprit drugs. Meta-analyses of specific HLA alleles from Thai and Asian BL-HSR studies were carried out using random-effects model. Results: Thirty-seven patients were included (62.16% IR, 21.62% NIR-mild, 16.22% SCARs). Association analyses identified candidate susceptibility signals for BL-HSR including HLA-DQA1*01:04 (odds ratio (OR) 8.79; 95% confidence interval (CI) 2.01-29.87; adjusted p-value 0.029) and HLA-DQA1*05:05 (OR 5.03; 95% CI 1.66-12.74; adjusted p-value 0.029). HLA-DQA1*05:05 showed stronger association in IR (OR 6.96; 95% CI 2.01-19.25; adjusted p-value: 0.018). Penicillin-induced HSR were potentially associated with HLA-C*07:02, and β-lactamase inhibitor with HLA-DQA1*01:04. However, these signals were not robust in subsequent sensitivity analyses. Meta-analyses provided contextual support for previously reported high-risk alleles in BL-induced SCARs. Conclusion: HLA-DQA1*01:04 and HLA-DQA1*05:05 represent candidate susceptibility signals for BL-HSR in Thai adults, with phenotype- and drug-specific patterns, which require independent validation. These findings, given relatively small sample size and use of population-based controls, may suggest basis for future immunogenetic risk stratification with validation in larger, phenotype-specific populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.